Table 2

Pathological features of Israeli prostate cancer cases by carrier status

Pathology characteristicCarriersNon-carriersOR95% CIp
n=29(%)n=145(%)
*Numbers too small for estimation of odds ratio
¶In the matched analysis, only five sets had both a case and at least one control that could be evaluated. Two of the cases, and none of the controls, had extra prostatic extension.
†In the matched analysis, only one set had both a case and a control that could be evaluated. The case had seminal vesicle involvement, but the control did not.
Benign and pre-neoplastic features
Atrophy3101181.400.32–5.00.72
Benign prostatic hyperplasia51619131.430.45–4.20.76
Chronic prostatitis93123162.470.93–6.40.06
Basal cell hyperplasia131070.440.02–3.30.70
Atypical adenomatous hyperplasia0021*
Atypical small acini proliferation13960.560.02–4.10.69
Prostatic intraepithelial neoplasia
Low grade1317120.290.01–1.780.32
High grade31022150.670.15–2.370.57
Low or high grade41438260.490.13–1.390.23
Adverse pathological features
Perineural invasion165577531.080.48–2.471.00
Lymphovascular invasion005300.00–4.80.59
Neuroendocrine features6211392.70.88–8.10.09
Extra prostatic extension31064
Seminal vesicle involvement1321
Any adverse feature217295661.400.54–3.50.51
Mean Gleason Score7.17.00.70